Literature DB >> 6300073

Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction.

L Thelander, A Gräslund.   

Abstract

The iron chelate of 1-formylisoquinoline thiosemicarbazone is one of the most potent inhibitors known for mammalian ribonucleotide reductase. In this study, we show that the target for the drug is the tyrosine free radical of the M2 subunit of the enzyme. The radical is destroyed by the drug in a reaction which requires oxygen. After removal of the drug, the tyrosine radical and ribonucleotide reductase activity can be regenerated by incubation of the enzyme with dithiothreitol. We propose that the iron chelate of the drug binds at the active site of the enzyme, and then the ferrous form of the chelate reacts with molecular oxygen in a redox process that, via a 1-electron reduction, leads to destruction of the M2 tyrosine radical.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300073

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

Authors:  F Wang; P Jiao; M Qi; M Frezza; Q P Dou; B Yan
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

2.  Biological assays and noncovalent interactions of pyridine-2-carbaldehyde thiosemicarbazonecopper(II) drugs with [poly(dA-dT)](2), [poly(dG-dC)] (2), and calf thymus DNA.

Authors:  Rebeca Ruiz; Begoña García; Javier Garcia-Tojal; Natalia Busto; Saturnino Ibeas; José M Leal; Célia Martins; Jorge Gaspar; Joaquín Borrás; Rubén Gil-García; Marta González-Alvarez
Journal:  J Biol Inorg Chem       Date:  2010-01-20       Impact factor: 3.358

3.  Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities.

Authors:  D R Richardson
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.

Authors:  T Spector; D R Averett; D J Nelson; C U Lambe; R W Morrison; M H St Clair; P A Furman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.

Authors:  Staci L Haney; Michelle L Varney; Hannah R Safranek; Yashpal S Chhonker; Narendran G-Dayanandan; Geoffrey Talmon; Daryl J Murry; Andrew J Wiemer; Dennis L Wright; Sarah A Holstein
Journal:  Leuk Res       Date:  2018-12-21       Impact factor: 3.156

6.  Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.

Authors:  Erika M Becker; David B Lovejoy; Judith M Greer; Ralph Watts; Des R Richardson
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 7.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

Review 8.  Iron and cancer: more ore to be mined.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Nat Rev Cancer       Date:  2013-04-18       Impact factor: 60.716

9.  Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species.

Authors:  Yimon Aye; Marcus J C Long; JoAnne Stubbe
Journal:  J Biol Chem       Date:  2012-08-22       Impact factor: 5.157

10.  Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity.

Authors:  Thomas J F Nieland; Jared T Shaw; Firoz A Jaipuri; Jay L Duffner; Angela N Koehler; Sotirios Banakos; Vassilis I Zannis; Tomas Kirchhausen; Monty Krieger
Journal:  Biochemistry       Date:  2007-12-08       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.